Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and cognitive function

This article was originally published in The Tan Sheet

Executive Summary

Low-dose aspirin use does not protect older women from cognitive decline, according to a randomized, double-blind study published on the British Medical Journal's Web site April 27. Conducted by Jae Hee Kang, et al., Brigham and Women's Hospital in Boston, the nearly 10-year study evaluated 6,377 women aged 65 and older who were taking part in the Women's Health study. Subjects were divided into two treatment groups: low-dose aspirin and placebo. Cognitive performance measured at 5.6 years and 9.6 years of treatment were similar among the groups. Although results suggest category fluency was better in the aspirin group, authors stress the finding should be interpreted "with caution," concluding "other methods for preserving cognitive function in older people need to be investigated." A study in the April 18 issue of the Journal of the National Cancer Institute and a recent Consumers Union report finds aspirin use was associated with decreased risks of certain cancers and heart attack, respectively (1"The Tan Sheet" April 23, 2007, p. 8 and 2"The Tan Sheet" April 23, 2007, p. 10)...

You may also be interested in...



Aspirin Tops Three Rx Drugs In Preventing Heart Attack – Consumers Union

Aspirin is the blood thinning agent of choice over three prescription antiplatelet medications for preventing first or repeat heart attack or stroke, according to a Consumers Union report

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel